972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial

Zalcman, G; Flandin, A-C. Madroszyk; Molinier, Olivier; Dayen, C.; Egenod, T.; Debieuvre, D.; Beaucaire-Danel, Sophie; Dixmier, A.; Pichon, E.; Girodet, S. Galland; Giroux-Leprieur, E.; Cloarec, N.; Cadranel, J.; Otto, Josiane; Romand, P.; Langlais, Alexandra; Morin, Franck; Antoine, Martine; Westeel, V.; Toffart, A.C.

doi:10.1016/j.annonc.2022.07.1100

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recently presented phase III IFCT-1701 DICIPLE compared treatment with nivolumab plus ipilimumab for 6 months versus continuation until progression for patients with treatment-naïve advanced NSCLC. 40 Patients who relapsed in the discontinuation arm were permitted to be rechallenged with the same drugs. This trial was prematurely closed after 32 months as the nivolumab and ipilimumab combination failed to be licensed in Europe, where the trial was conducted.…”

Section: Optimal Duration Of Therapymentioning

confidence: 99%

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Kuah,

Monfries,

Quartagno

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown. Focusing on anti-PD1 agents nivolumab and pembrolizumab in the context of non-small cell lung cancer, we argue that several lines of evidence suggest current administration regimens of these drugs may result in overtreatment with potentially important implications for cost, quality of life and toxicity. This review summarizes evidence for the scope to optimize anti-PD1 regimens, the limitations of existing data and potential approaches to solve these problems including with a novel multi-arm clinical trial design implemented in the recently opened REFINE-Lung study.

show abstract

Section: Optimal Duration Of Therapymentioning

confidence: 99%

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Kuah,

Monfries,

Quartagno

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…Whether a shorter course of maintenance immunotherapy would produce a similar result, or a longer course would prolong the OS remains a topic of interest. CheckMate-153, randomizing patients to observation or continuous nivolumab upon completion of 1 year of immunotherapy revealed improved survival outcomes with continuation while IFCT-1701 trial which was halted prematurely, randomizing patients to observation or continuous nivolumab and ipilimumab upon completion of 6 months did not demonstrate a survival benefit ( 25 , 26 ). In addition to the duration of immunotherapy, the outcomes of rechallenge with immunotherapy upon progression are of interest.…”

mentioning

confidence: 99%

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Daylan¹,

Halmos²

2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non–Small Cell Lung Cancer: A Single Institution Database Analysis

Kobayashi

Wakuda

Naito

et al. 2023

Clinical Lung Cancer

View full text Add to dashboard Cite

972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial

Cited by 8 publications

References 0 publications

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non–Small Cell Lung Cancer: A Single Institution Database Analysis

Contact Info

Product

Resources

About